Book chapter
CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders - Chapter 6
Monoclonal Antibodies in Headache, pp.69-97
Springer
2021
DOI: 10.1007/978-3-030-69032-8_6
Abstract
As our understanding of the importance of calcitonin gene-related peptide (CGRP) in headache disorders has evolved, the therapeutic use of CGRP monoclonal antibodies has marked a new era in the headache field. Anti-CGRP antibodies that block either the ligand or the receptor are effective in the prevention of migraine and cluster headache. Nevertheless, there are still many uncertainties about mechanisms underlying the effects of CGRP and the antibodies that target either the ligand or the receptor in headache disorders. In particular, whether CGRP and the anti-CGRP antibodies act through peripheral or central actions remains vigorously debated. Studies utilizing animal models of headache disorders have generated important clues that can help in this debate. This review aims to explore the advances on the effects and action sites of anti-CGRP antibodies in different animal models of headache disorders, with an emphasis on migraine, but also including animal models of secondary headaches, including post-traumatic headache (PTH) and medication overuse headache (MOH). Based on current preclinical studies, anti-CGRP antibodies are able to inhibit trigeminal pathways involving Aδ meningeal nociceptors and high threshold (HT) neurons in the spinal trigeminal nucleus, and vasodilation of dural vessels.
Details
- Title: Subtitle
- CGRP Antibodies for Animal Models of Primary and Secondary Headache Disorders - Chapter 6
- Creators
- Mengya WangAnne-Sophie WattiezAndrew F Russo
- Resource Type
- Book chapter
- Publication Details
- Monoclonal Antibodies in Headache, pp.69-97
- DOI
- 10.1007/978-3-030-69032-8_6
- Publisher
- Springer; Cham, Switzerland
- Language
- English
- Date published
- 2021
- Academic Unit
- Neurology; Molecular Physiology and Biophysics; Iowa Neuroscience Institute; Craniofacial Anomalies Research Center
- Record Identifier
- 9984083945702771
Metrics
49 Record Views